Saturday 17 October 2026
Export BIOA’s income statement to Excel — free account
BioAge Labs, Inc.
BIOA Healthcare Drug Manufacturers Specialty & Generic
BioAge Labs, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.0 million. In the quarter to June 2026, revenue grew 1.62%, EPS grew 3.33%, free cash flow grew 2.68% and total debt fell 83.6%, each against the same quarter a year earlier.
4.82
0.53
−9.91%
Follow BIOA
| Dec '25 | Dec '24 | Dec '23 | |
|---|---|---|---|
P/E ratio |
0.00 | — | — |
Altman Z-Score |
10.98 | — | — |
P/S ratio |
52.85 | — | — |
P/FCF ratio |
0.00 | — | — |
Altman Z″-Score (non-manufacturers) |
12.64 | — | — |
P/Operating CF |
(16.83) | — | — |
P/B ratio |
1.75 | — | — |
Price to Tangible BV |
1.75 | — | — |
EV/Sales |
22.01 | — | — |
EV/EBITDA |
0.00 | — | — |
EV/Operating CF |
(2.43) | — | — |
EV/FCF |
(0.84) | — | — |
Quick Ratio |
14.00 | 12.76 | 0.43 |
Current Ratio |
14.24 | 12.86 | 0.44 |
Net Debt/EBITDA |
3.01 | 4.43 | 0.22 |
Debt/Assets |
0.90% | 2.37% | 54.78% |
Debt/Equity |
0.01 | 0.03 | (0.08) |
Asset Turnover |
0.03 | 0.00 | — |
Operating CF/Net income |
1.01 | 0.72 | 0.59 |
Capex/Depreciation |
(729.89) | (2.19) | (1.02) |
Interest Coverage |
(133.11) | (33.04) | (6.21) |
| (27.09%) | (94.98%) | 0.00% | |
| (24.68%) | (37.02%) | 0.00% | |
ROIC |
0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(30.12%) | (21.55%) | 196.24% |
Average Days of Receivables |
31.20 | — | — |
Research and Development Expense of Revenue |
822.30% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
309.16% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
129.97% | 0.00% | 0.00% |
Graham Net Nets |
0.56 | — | — |
Graham Number |
0.00 | — | — |
Earnings Yield |
(16.93%) | — | — |
Free Cash Flow Yield |
(49.87%) | — | — |
Revenue per Share |
0.25 | 0.00 | 0.00 |
Operating CF per Share |
(2.27) | (4.80) | (22.33) |
Capex per Share |
(4.33) | (0.03) | (0.10) |
Free Cash Flow per Share |
(6.60) | (4.84) | (22.43) |
Cash per Share |
7.82 | 33.03 | 14.92 |
Shareholders Equity per Share |
7.57 | 30.12 | (103.66) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
7.57 | 30.12 | (103.66) |
Free Cash Flow |
(237.09) | (51.89) | (37.53) |
Working Capital |
266.66 | 329.33 | (32.86) |
Capital Expenditures |
(155.47) | (0.37) | (0.17) |
Net Current Asset Value |
263.96 | 322.00 | (174.01) |
EV/EBIT |
0.00 | — | — |
Capex to Sales |
17.28 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | — | — |
| Other line items | |||
Depreciation/Fixed assets |
0.22 | 0.28 | 0.50 |
Cash ROIC |
(42.66%) | (7.56%) | 27.96% |
Accounts Receivable Turnover |
0.00 | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 |
Average Payables |
2.34 | 1.93 | — |
Average Assets |
326.56 | 192.08 | — |
Average Common Equity |
297.59 | 74.87 | — |
Columns are period end dates